Truist raised the firm’s price target on Arcellx (ACLX) to $136 from $87 and keeps a Buy rating on the shares after its Q3 results. The ...

Scotiabank raised the firm’s price target on Arcellx (ACLX) to $133 from $82 and keeps an Outperform rating on the shares. The firm adjusted its model following “highly compelling results” reported ...

Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Arcellx (NASDAQ:ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for its ...

Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued on ...

Arcellx (NASDAQ:ACLX – Free Report) had its price objective boosted by Bank of America from $84.00 to $100.00 in a research ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

It’s an exciting time at Arcellx! We are preparing for the commercial launch of anito-cel as there remains an unmet need for a therapy that physicians can use across a broad patient population.” ...